US-based pharma company Abbott Laboratories (Abbott) announced on 23 June 2014 that it had signed a definitive agreement to acquire Russian generics maker Veropharm.
Abbott to buy Russian generics firm
Home/Pharma News
|
Posted 04/07/2014
0
Post your comment

The deal will see Abbott pay between US$395 and US$495 million for one of the leading generics makers in Russia. The purchase is expected to expand Abbott’s worldwide drug manufacturing capabilities and strengthen its commitment to Russia, where it has had a presence for 40 years.
The acquisition will give Abbott access to a portfolio of medicines that is well aligned with its current pharmaceutical therapeutic areas of focus in women’s health, central nervous system, cardiovascular and gastroenterology, while also adding an offering in the field of oncology.
Abbott has been rapidly expanding its generics portfolio, as well as its presence around the globe. The healthcare major expanded its presence in Latin America with the purchase of CFR Pharmaceuticals in May 2014 [1]. While back in 2010 the company bought the domestic unit of Piramal Healthcare, one of India’s biggest generics makers [2].
References
1. GaBI Online - Generics and Biosimilars Initiative. Abbott expands generics business in Latin America [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2014 Jul 4]. Available from: www.gabionline.net/Pharma-News/Abbott-expands-generics-business-in-Latin-America
2. GaBI Online - Generics and Biosimilars Initiative. Abbott acquires Indian generics’ maker Piramal Healthcare [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2014 Jul 4]. Available from: www.gabionline.net/Pharma-News/Abbott-acquires-Indian-generics-maker-Piramal-Healthcare
Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.
Copyright – Unless otherwise stated all contents of this website are © 2011 Pro Pharma Communications International. All Rights Reserved.
Source: Abbott
Guidelines
FDA issues guidance on AI use in drug and biologicals regulatory decision making
ICH adopts Good Clinical Practice Guideline for clinical trials
Policies & Legislation
NPRA Malaysia trials new timelines for variation applications
Regulatory evolution and impact of simplified requirements for interchangeable biosimilars in the US
Most viewed articles
The best selling biotechnology drugs of 2008: the next biosimilars targets
Global biosimilars guideline development – EGA’s perspective
Related content
Bio-Thera partners with Tabuk in Saudi Arabia and SteinCares in LATAM
Klinge-Teva and MS Pharma agreements for Eylea and Stelara biosimilars in Europe and MENA
Biosimilars thrive as China’s biotech industry gains momentum
Greener Pharmaceuticals: WHO's call for innovative regulatory practices and eco-friendly innovations
Bio-Thera partners with Tabuk in Saudi Arabia and SteinCares in LATAM

Home/Pharma News Posted 18/02/2025
Klinge-Teva and MS Pharma agreements for Eylea and Stelara biosimilars in Europe and MENA

Home/Pharma News Posted 06/02/2025
Greener Pharmaceuticals: WHO's call for innovative regulatory practices and eco-friendly innovations

Home/Pharma News Posted 15/01/2025
The best selling biotechnology drugs of 2008: the next biosimilars targets

Post your comment